Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Breast Neoplasms
  • Immunoconjugates

abstract

  • Glembatumumab vedotin has an acceptable safety profile. Preliminary evidence of activity in treatment-resistant metastatic breast cancer requires confirmation, such as the phase II randomized trial (EMERGE) that also examines the relationship between activity and gpNMB distribution/intensity.

publication date

  • November 10, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.52.5683

PubMed ID

  • 25267761

Additional Document Info

start page

  • 3619

end page

  • 25

volume

  • 32

number

  • 32